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Abstract: In the field of pharmaceutical technology, significant attention has been paid on exploiting
skin as a drug administration route. Considering the structural and chemical complexity of the
skin barrier, many research works focused on developing an innovative way to enhance skin drug
permeation. In this context, a new class of materials called bio-functional textiles has been developed.
Such materials consist of the combination of advanced pharmaceutical carriers with textile materials.
Therefore, they own the possibility of providing a wearable platform for continuous and controlled
drug release. Notwithstanding the great potential of these materials, their large-scale application still
faces some challenges. The present review provides a state-of-the-art perspective on the bio-functional
textile technology analyzing the several issues involved. Firstly, the skin physiology, together with the
dermatological delivery strategy, is keenly described in order to provide an overview of the problems
tackled by bio-functional textiles technology. Secondly, an overview of the main dermatological
nanocarriers is provided; thereafter the application of these nanomaterial to textiles is presented.
Finally, the bio-functional textile technology is framed in the context of the different dermatological
administration strategies; a comparative analysis that also considers how pharmaceutical regulation
is conducted.
Keywords: textiles; biomedical materials; regulatory issues; skin; transdermal drug delivery;
nanocarriers; electrospinning; encapsulation; fibers
1. Introduction
In the last decades, research in the field of pharmaceutical technology has invested significant
efforts in the development of innovative formulations for smart drug delivery [1,2]. This concept
lies in the idea of administering a controlled dosage of active substance to the patient in order to be
therapeutically effective while minimizing over dosage and side effects [3]. Among these innovative
drug delivery technologies, the possibility of exploiting skin for pharmaceutical administration has
aroused significant interest [4,5]. Indeed, skin is the largest organ of the human body and displays a
significant surface area for drug administration [6]. Moreover, being the organ devoted to the internal
body protection, skin can act as a barrier for harmful substances thus reducing possible side effects [7].
Therefore, skin has been considered as a possible administration route both for systemic and local
drugs. According to Food and Drug Administration (FDA), the first case is defined as transdermal
administration and involves the delivery of the drug through the skin layers in order to reach systemic
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circulation, while the latter is defined as topical administration and consists of the application of the
active molecule on a particular area of the body surface [8,9]. Transdermal administration displays
several advantages compared to other classic drug delivery routes such as the enteral and parenteral
ones [10]. Firstly, it is noninvasive since it does not require injections. Secondly, it delivers the actives in
the blood circulation avoiding the first pass metabolism in the liver [11]. Lastly, given that transdermal
delivery devices can stick on the patient for several days, the number of required applications is
significantly reduced; significantly improving the patient compliance to the therapy [12].
Notwithstanding the numerous advantages of the transdermal route, two main issues significantly
limit its employment. In fact, the skin barrier is characterized by a great chemical complexity that
limits the transport of the active substances across its numerous layers. Therefore, only a few
classes of active molecules could effectively cross it to reach systemic circulation [13,14]. In order to
increase the skin penetration capability of active molecules several strategies have been developed,
which include use of both physical and chemical penetration enhancers [15–17]; however, some of these
penetration enhancement strategies may result in irritating the skin in the long run [18,19]. The recent
advances in nanotechnology are providing very promising solutions consisting of the development
of pharmaceutical carriers that can vector the active molecules through the skin layers [20,21].
Moreover, to limit the risk of skin irritation, much attention is paid on the usage of biocompatible
materials, to which skin can stand a long period contact without side effects, such as breathable textile
materials [22–24].
In recent years, textile research has focused on development of the so-called “functional textiles”
that are designed and produced not for apparel and aesthetic purpose, but for their technical properties
and performances [25,26]. The application of technical textiles is broad and deals with several
fields such electronics [27,28], automotive and aerospace [29,30], construction and buildings [31–33],
protective garments [34,35] and medical textiles [36,37]. The latter application includes textiles
that aim to be beneficial to the wearer’s health by owing peculiar features such as antibacterial
action [38,39], protection against insects and parasites [40,41], antioxidant [42,43] and ultimately drug
releasing properties [44,45]. Bio-functional textiles are produced by integrating conventional textiles
and advanced pharmaceutical nanocarriers in order to provide wearable drug delivery systems,
both for topical and transdermal active therapies [46,47]. Indeed, bio-functional textiles are promising
products given their capability of improving dermal penetration of the active molecule and at the
same time avoiding toxicity risk by employing bio compatible materials [48]. The potential societal
impact of bio-functional textiles technology has catalysed a very significant interest in different
scientific communities such as pharmaceutical technologists, textile engineers, materials science
researchers, and chemists. Therefore, a clear understanding of the topic requires a multidisciplinary
and comprehensive approach.
The present review aims to gather the most significant and recent contributions on bio-functional
textiles for transdermal release and to analyze and classify them critically. The aim is to provide a
set of information readily usable by scientists of different fields. Firstly, this manuscript describes the
physiological nature of the dermal tissues in order to clarify the present challenges in crossing the skin
barrier. After that, an overview of the mechanisms by which a substance can pass through the skin
layers is provided together with the standard methodologies of penetration enhancement. Among the
penetration enhancement techniques, significant attention is paid to the pharmaceutical nanocarriers
inquiring the most relevant ones for dermatological applications. Furthermore, the potential of
integrating the above-mentioned nanocarriers with textiles is discussed by analyzing the most common
textile materials and finishing techniques. A special focus is also given on critically reviewing the
different testing methodologies proposed to characterize the performance of bio-functional textiles
both from the materials and the biological point of view. Finally, some critical considerations
regarding the potential development of this technology are drawn, considering the regulatory issues
for commercialization of these innovative products.
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2. Nature and Physiology of the Skin
Skin is the organ of the human body which presents the highest surface area, and it complies
with essential body functions. Above all, it is a chemical and physical barrier that protects
the internal tissues from the external harms such as virulent pathogens, UV light and toxic
substances. Moreover, skin complies to thermal regulation, water retention, sensitive detection
and self-healing [49,50]. Structurally speaking, skin consists of a series of stratified layers which are
sketched and described in Figure 1. The two main skin layers are the dermis and the epidermis [51].
The epidermis is the outer skin layer and is divided into multiple layers; it is mostly constituted
by keratinocytes. Keratinocytes are the most diffuse skin cells which are formed in the lowermost
epidermal layer, the Stratum Basale and raise to the outermost Stratum Corneum (SC) undergoing
keratinization and cellular differentiation [52]. The keratinocytes present in the SC have already
undergone terminal differentiation and are therefore present as dead cells without nucleus named
corneocytes [53]. These keratin-rich cells present a flat shape, which are bound together by lipids such
as ceramides, fatty acid and cholesterol; the array of corneocytes and intercellular lipids imparts the
SC a “brick and mortar” structure [54]. Right below the SC the Stratum Lucidum is found; this skin
layer consists of a single or double layer of partially denuclearized keratinocytes bound together by
the eleidin, a lipoprotein that imparts a translucent appearance to this skin layer. It is present only in
certain parts of the human body such as feet, palm, and lips [55]. The Stratum Granulosum is located
under the Stratum Lucidum, in these layers the keratinocytes own a nucleus and are of granular shape.
At this differentiation level, the cells also contain keratohyalin granules, which are rich in the proteins
that bind keratin. In this layer the cells secret the interlamellar lipids found in SC; therefore, they are
responsible for the skin barrier properties [56]. The under located Stratum Spinosum is constituted
by several rows of spine shaped keratinocytes, other cells present in this layer are the melanocytes
and the Langherans cells [57]. Melanocytes synthesize melanin and are therefore responsible for skin
pigmentation and UV protection, Langherans cells instead contribute to the immune response of the
skin [57,58]. On the bottom of the epidermis, the Stratum Basale is composed by a single layer of stem
keratinocytes, these cells have large nuclei and high reproduction rate, once produced the stem cell
raise to the upper layer gradually differentiating [59]. In the Stratum Basale, together with melanocytes
and Langerhans cells, the Merkel cells are found. The latter complies with the role of touch sensors [60].
The Dermal-Epidermal Junction (DEJ) consists of a basement membrane with a laminar structure
and binds the dermis and the epidermis together. The DEJ is composed by the Lamina Lucida and the
Lamina Densa [61]. The Lamina Lucida is about 50 nm thick, and it has a translucent appearance under
transmission electron microscope (TEM) observation; it is mainly composed of laminin, a glycoprotein
that interacts with IV type collagen contributing to the binding between epithelial and connective
tissues [6,62]. The Lamina Densa is instead thicker (200–300 nm) and mainly composed of IV and
VII type collagen together with dermal fibrils and microfibrils [63]. The dermis is located between
the DEJ and the subcutaneous tissues (hypoderm); it is vascularized and characterized by a layered
structure that can be divided into the papillary and reticular dermis. The Papillary dermis is primarily
constituted of connective tissue; it is rich in blood vessels and nerve terminations. It tends to form pegs
and ridges with the DEJ; this increases the contact area between dermis and epidermis. The reticular
dermis is mainly composed of elastic collagen and oriented fibrous matrices which impart elasticity
flexibility and strength to the skin [64]. In this zone the sweat glands are found that contribute to
the body thermal regulation, and the hair follicles, which can act as keratinocytes source during the
re-epithelialization process. The reticular dermis is attached to subcutaneous tissues without sharp
distinctions. The hypodermis is mainly constituted of connective tissue and attaches the skin to the
muscular tissues. It is composed of three layers: the top one is rich of fatty substances while the bottom
two are vascularized [65]. By observing the overall skin architecture, a complex structure from the
biochemical point of view can be easily observed. The alternation of fatty hydrophobic layers and
vascularized hydrophilic ones makes it difficult for chemical substances to cross it. Indeed, this natural
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protection can also act as a shield against therapeutic molecules; therefore, several strategies have been
developed in order to make them easily cross the skin barrier [66].
Figure 1. Scheme of skin layers. The references in the image point out: (1) hair shaft; (2) stratum
corneum; (3) sweat-pore; (4) hair follicle; (5) arrector pili muscle; (6) sebaceous gland; (7) nerve;
(8) eccrine sweat gland; (9) cutaneous vascular plexes; (10) adipose depot. Section (A) and (B) highlight
a detailed structure of the epidermis and derma respectively. [Reproduced from Gaur et al. [67]
which is licensed under a Creative Commons Attribution-(CC BY 4.0) International License (http:
//creativecommons.org/licenses/by/4.0/)].
3. Skin Interaction with Drugs and Current Challenges in Dermatological Delivery
The significant surface area of the skin has made it an attractive target for drug administration;
however, its structural and chemical complexity makes dermatological drug delivery a complex field
of study [68]. When dealing with the delivery of active substance to the skin, a significant distinction
must be made according to the therapeutic target. Indeed, as previously mentioned, if the therapy
aims to act on the skin itself it will be defined as topical administration while if it aims to cross the skin
barriers to deliver the drug in the blood vessels, it will be defined as transdermal release [69].
Topical (or dermal) delivery is among the most commonly used administration routes and in
general consists in applying the medicament directly on the target tissue and it commonly applies to
dermatological and ocular formulations [70,71]. In the dermatological therapies, this local approach
is widely used to treat the illnesses that regard the dermis and the epidermis, such tissues being the
natural shield that protects the human body from external treat can be affected easily by wounds
and infections [72,73]. Common topical release strategies have been used to treat skin diseases such
as psoriasis, atopic dermatitis, wounds and skin ulcers [74–76]. Such illnesses have been shown to
have a substantial impact on patient life, and in the case of severe wounds and ulcers, the patient
can be hospitalized and obliged to undergo surgical intervention. For this reason, in recent years,
many research efforts have been made in order to allow a more efficient and continuous topical
delivery of active substances [77]. Indeed, in the case of chronic wounds, a continuous, prolonged and
controlled release of active substances was identified as a smart strategy to stop the advancement of
the infection [78]. In addition, the development of biomedical devices that provide a substrate for the
re-growth of the skin tissue while topically releasing drug is arising from significant interest [79].
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Transdermal release involves the penetration by the drug of the skin layers in order to reach the
vascularized regions on the epidermis and operate a systemic effect [80]. In Figure 2, the phenomena
acting in transdermal release are sketched. For a substance to reach the dermis, three penetration
pathways are commonly identified [81,82]. The intercellular route involves the passage around the
corneocytes, and the molecules diffuse in the lipid substances that hold the terminally differentiate
keratinocytes together, thus such route is generally preferred by lipophilic substances [83]. Oppositely,
the intracellular pathway is preferred by hydrophilic substances that cannot diffuse easily in the lipid
extracellular network of the SC. This route involves the penetration of the drug through the corneocytes
cells [84]. A third path, defined as annexial (or follicular) route, consists of the passage of the drug
through the skin annexes such as hair follicles or sweat glands [85]. Notwithstanding that the annexial
route allows easy penetration of different drugs across the epidermis, it must be taken into account that
skin annexes represent only a small percentage of the overall skin surface and therefore most of the
mass transfer occurring in the skin penetration phenomenon would exploit the intra- and extracellular
pathways [86].
Figure 2. Transdermal transport and penetration pathway (reproduced from Bolzinger et al. (2012) [87],
with permission from Elsevier).
The percutaneous absorption of a drug can be regarded as a mass transfer phenomenon that
involves several steps whose kinetics is mainly dominated by diffusion [88,89]. The first step consists
of the entry and penetration of the drug into the SC. Secondly, the drug must partition from the SC into
the viable aqueous epidermis reaching the Stratum Basale. The drug must then diffuse through the
Stratum Basale in order to reach and permeate the Dermal-epidermal junction. Once it has reached
the dermis, the drug must be absorbed by the blood vessels in order to finally enter the systemic
circulation [90,91]. The complexity of transdermal penetration lies in the fact that it requires alternate
diffusion through different layers and permeation across the boundaries that separate them. Each layer
(and boundary) has its own different chemical composition and therefore different resistance to mass
transfer. Since a limited diffusion in one single skin layer may hinder the overall penetration process,
the amount of active substances easily deliverable transdermally is quite reduced [92]. Common rules
found in literature state that in order to cross the SC easily, a molecule should own lipophilic character
and small size, i.e., lower than 500 Da; the latter condition is widely known as the 500 Daltons rule [93].
However, lipophilic molecules have also been recently considered to have not optimal penetration
capability; indeed, according to some authors, they can easily cross the SC but thereafter cannot diffuse
in the vascularized layers, and therefore they tend to accumulate in the SC [94]. A further point to
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consider is the huge variability of the skin in terms of thickness, chemical composition, and biological
activity. Such parameters tend to change in different individuals, the factors that influence the skin
physiology include but are not limited to age, sex, phototype and health practices of the patient [95].
Moreover, the relative properties of the individual skin layers can also change in different parts
of a single body. For these reasons, the transdermal penetration of a drug is an overall complex
phenomenon [96]. Finally, some authors also recently pointed out how skin health status changes the
transdermal delivery kinetics [97,98].
Despite the complexity of the transdermal administration route, its potential advantages have
driven the scientific community to develop innovative technologies in order to enhance skin penetration
by active substances. The physical transdermal penetration strategies consist of applying external
stimuli such as electric current or ultrasound to help the drug to cross the epidermal layer [17,99].
The application of low electric current is defined as iontophoresis [100] while the application of
ultrasounds (US) is called sonophoresis [101]. Another physical enhancement technology is the
Microneedles (MN) one; this technology employs micrometric size needles to pierce the epidermis and
deliver the drug directly in the vascularized layers [102,103]. Chemical enhancement instead consists
of adjusting the drug formulation by adding appropriate chemical substances that cause the swelling
of skin barrier [104]. A further skin penetration enhancement strategy consists of the incorporation of
the active substance into nanocarriers; such devices can be designed in order to possess physical and
chemical properties that allow them to drive the drug across the skin barrier to reach the systemic
circulation without affecting the outer skin integrity [105,106]. Moreover, it is possible to combine
some pharmaceutical nanocarriers with textile material in order to produce wearable drug delivery
devices. The drug encapsulation is, in fact, one of the most promising technological advancements in
the pharmaceutical fields, and for this reason, a deeper discussion is dedicated to it and its application
to transdermal drug delivery [107].
4. Pharmaceutical Nanocarriers for Dermatological Applications
Pharmaceutical nanocarriers are a nanoscale technology that has been developing over the last
decades, given the necessity of administering pharmaceutically active substances most effectively.
The encapsulation process is the technique to incorporate active molecules inside nanostructured
materials with monolithic or core-shell structure [108]. This process can indeed improve the
performances of the active material under many points of views. Firstly, the nanomaterial can protect the
drug from environmental factors that alter its biological activity [107,109]. Secondly, the encapsulation
process allows to control the structure of the core material in order to regulate its interactions with
the environment: as an example, such a technique is commonly used to enhance biostability and
bioavailability of poorly water-soluble drugs in the blood stream [110]. Lastly, encapsulation allows
releasing the drug in a prolonged and controlled manner providing an effective therapeutic dosage
while minimizing sides effects [111]. The most advanced encapsulation technologies can release the
drug only if required conditions are verified, making the system stimuli responsive. The encapsulation
process is employed to obtain different products and pharmaceutical dosage forms. These formulations
are classified according to their chemical nature, structure, morphology, and assemblies. For dermal
and transdermal applications, the most studied carriers are micro- and nanoparticles, either polymeric
and lipidic, cyclodextrin-based, hydrogels and liposomes [112,113].
Particulate systems are among the most studied carriers; they are classified according to their
average size (microparticles, nanoparticles), shell material (organic, inorganic, hybrid) and their
morphology and structure (spheres, capsules and bubbles) [114]. In dermatology, the nanosized
particles present a wider application range, given their higher capability of penetrating the skin barrier
both by intra/extra cellular route and by annexial one. In fact, given the submicronic size of the skin
annexes, nanoparticles can pass through them. On the other hand, microparticles own a size that
hinders their penetration and are mostly applied in topical skin therapy [66,115]. Concerning the shell
nature, mostly polymeric materials are used. This trend is due to the large availability of biocompatible
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and biodegradable polymers that allows sustained release of the drug by diffusion/erosion of the
polymer matrix [116]. Moreover, ceramic materials, such as zinc oxide, can be also used for drug
delivery, combining the therapeutic action of the drug with the functional properties of the shell such as
antimicrobial or UV light protection [117,118]. According to the structure, polymeric nanocarriers are
commonly divided into nanospheres, characterized by a solid structure in which the drug is dispersed
in the polymer matrix, nanocapsules, which own a defined core in a liquid state and shell structure,
and nanobubbles, spherical core/shell structures filled by a gas or vaporizable compounds [114].
Several authors proposed the application of nanospheres to enhance drug penetration, among them
Lalloz et al. [119] deeply studied the effect of the particles’ surface charge on skin penetration. In their
work, vitamin D (logP = 7.5) was incorporated in purposely synthesized block copolymers by employing
flash nanoprecipitation, a productive nanoparticle production technique (a technique that has been
well-described, for example by Lavino et al. [120]). Permeation studies, conducted both on healthy and
damaged pig skin, showed a limited effect of the nanoparticle surface charge on the healthy skin while
particle polarity affected the release kinetics in the case of damaged skin tissue [119]. By employing
a similar particle production methodology, our research group designed poly-ε-caprolactone (PCL)
nanoparticles for the delivery of the strongly hydrophilic caffeine molecule (logP = −0.07). The results
proved that selection of different solvent for the drug molecule during precipitation process could affect
drug partition between the core and the surface of the sphere effecting the release kinetics through the
skin annexes [121,122].
Nanocapsules usually present a well-defined core and shell structure. Such devices can either
penetrate SC as whole or disrupt and allow the oily core to diffuse in the epidermis. In the work of
Pereira [123] adapalene (logP = 8.5) loaded PCL nanocapsules were produced and topically applied: the
high hydrophobicity of both carrier and drug facilitated diffusion in the SC but no further penetration
was observed, making the system suitable for topical administration. Marto et al. [70–124] incorporated
an anti-inflammatory drug in starch-shelled nanoparticles by emulsion solvent evaporation method.
The potential effectiveness of such topical formulation was evaluated both in vitro and in vivo on
rats showing an improved efficacy compared to commercial cream formulation. In the study of
Mathes [125], the relative performances of both nanospheres and capsules were compared to target hair
follicles with glucocorticoids. The particles were prepared by nanoprecipitation solvent evaporation
methods, marked with fluorescent dyes and tested both on pig and human skin. This study evidenced
how improved targeting of the hair follicles resulted in the drug to be delivered by annexial transport
rather than SC permeation. Among the different employed carriers, the nanocapsules displayed a
more marked follicular targeting than the nanospheres.
Polymer shelled nanobubbles (NBs) and nanodroplets (NDs) represent another nanotechnology
exploited for cutaneous administration of active molecules. They are versatile multifunctional core-shell
nanocarriers designed for the delivery of drugs, gases and genes [126]. The structural flexibility of
these core-shell systems allows efficient incorporation of several active molecules with high payload.
They have been proposed for local delivery of antimicrobial drugs for treatment of cutaneous infectious
diseases. Rifampicin-indocyanine green-loaded perfluorocarbon (PFC) nanodroplets were developed
as combined photo-chemo-probiotic therapeutics for the treatment of dermatoses caused by P. acnes
infection [127]. The combination of vancomycin-loaded NBs with ultrasound was studied to enhance
drug penetration through skin by sonophoresis and trigger drug release at the site of infection [128].
In vitro permeation studies with porcine skin showed that the amount of vancomycin accumulated in
the skin after US application combined with NBs was greater than the minimal inhibitory concentration
(MIC) value, whereas the passive transport through the skin of the free drug was negligible [128].
The feasibility of the use of NB system combined with US was also exploited to design a therapeutic
tool to topically treat hypoxia-associated dermal pathologies and promote wound healing process.
They showed effective oxygen storing capability and ability to release oxygen to cutaneous tissues
both in vitro and in vivo [129–133]. Skin oxygenation of mice topically treated with oxygen-loaded
NDs was monitored by visualizing the subcutaneous levels of oxy-hemoglobin and deoxy-hemoglobin
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through photoacoustic imaging and an increase in the tissue oxygenation with a prolonged oxygen
release over time was observed [134].
Cyclodextrins (CDs) are oligosaccharides chemically constituted by glucose rings arranged
in a toroidal structure [135]. Common CDs are formed by 6–8 glucose units; moreover, recent
discoveries proved the possibility of synthesizing cyclodextrins composed of 3 or 4 glucose units [136].
CDs have been widely exploited in pharmaceutical sciences due to their capability of including active
substances in their cavity improving drug dispersibility and bioactivity [137,138]. To improve their drug
loading content, several CDs-based supramolecular assemblies have been proposed and synthesized.
Nanosponges (NS) are solid nanoparticles consisting of cross-linked cyclodextrins nanostructured
within a three-dimensional network [139]. Thanks to their porous nanostructure they are capable
of encapsulating hydrophilic as well as hydrophobic molecules, providing sustained and controlled
release, improving solubility, stability, permeation and bioavailability [140]. Nanosponges can be
incorporated in topical formulations, improving the retention onto the skin of incapsulated drugs.
Pyromellitic nanosponges have been proposed as promising multifunctional co-ingredients in topical
monophasic and biphasic formulations. Skin permeation studies showed that NS in gels and cream-gels
containing diclofenac significantly modulate drug transport through the skin, increasing its amount in
stratum corneum and viable epidermis [141]. The same type of NS was exploited for the delivery of
imiquimod (IMQ), an immune response modifier. A hydrogel containing imiquimod-loaded NS was
formulated to control the scarring process for the treatment of aberrant wounds. Loaded NS could act as
a drug reservoir, able to slowly deliver IMQ through the skin, favoring dermal accumulation [142,143].
Permeation studies carried out on porcine skin and rabbit mucosa revealed an enhanced permeation
rate of resveratrol loaded in nanosponges compared to free drug [144]. Nanosponge-based hydrogels
have been also proposed for the treatment of skin infections. They were designed as alternative
carriers for targeting econazole nitrate (EN) to the skin to contrast fungal infection with minimal
side-effects [145]. Lemongrass oil-loaded ethyl cellulose nanosponges were developed, showing an
enhanced antifungal effect and decreased skin irritation [146].
Liposomes are vesicle-based carriers; they are typically constituted by a phospholipidic
bilayer with an aqueous core. Having an amphiphilic structure, liposomes can entrap either
hydrophilic or hydrophobic molecules in the aqueous core and in the lipid membrane, respectively.
Marhauser et al. [147] have shown that liposomes act as efficient carriers enhancing transdermal
drug release. Their approach consisted of preparing fluorescent labeled liposomes and testing their
penetration through porcine skin using Franz Cells. The evaluation of the skin penetration was
performed both by tape stripping of stratum corneum layer and by horizontal section of the skin
membrane followed by fluorescent microscopy observation. Deformable liposomes or transferosomes
have been designed to enhance the penetration behavior of traditional liposomes. The high elasticity
of these liposomes allows them to squeeze and penetrate the skin by different pathways [112,148].
Hong et al. [149] correlated the effectiveness of the skin transport of liposomal formulations to their
mechanical properties. Several formulations with various surfactants were prepared and then their
elasticity was measured, and the transdermal release was studied on a porcine skin model.
More recently, other vesicular nanosystems such as niosomes, ethosomes, transethosomes have
been studied to enhance the transdermal drug delivery [150]. Ethosomes are novel lipid vesicular
nanocarriers composed of phospholipid and a high percentage of ethanol, while transethosomes are
the new generation of ethosomal systems containing the basic components of classical ethosomes and
an additional compound, such as a penetration enhancer or an edge activator (surfactant) in their
composition. They can improve the penetration through stratum corneum by increasing the fluidity of
cell membrane lipids [151–154]. Hydrogels are systems constituted by polymeric chains dispersed in
water whose content can constitute up the 99% of the system weight. They are characterized by the
presence of several hydrophilic groups in the chains of the dispersed polymer and have a significant
efficiency in the encapsulation and the delivery of hydrophilic substances; their high content of water
also makes them a suitable material for wound and burn recovery [155]. Jeong and co-workers proposed
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a hydrogel-based transdermal delivery system obtained by crosslinking carboxymethyl chitosan with
hydroxyethyl acrylate via a free radical polymerization mechanism [156]. The synthesized hydrogel
network was exploited to load nobiletin with an encapsulation yield of 42%. The hydrogel was
proved to be biocompatible with skin tissue by an in vitro cytotoxicity test on keratinocytes cells
culture. The skin penetration test on micro pig dorsal skin showed that most of the incorporated drug
was released. Moreover, the different hydrogel formulations lead to a higher or lower transdermal
penetration for dermal retention, proving that the designed system allowed to achieve the drug delivery
in the desired therapeutic target. Taktak et al. [157] used a tri-block co-polymer to produce hydrogels
loaded with paclitaxel and heparin for cancer therapy. The formulation shown that can be effective in
a combined cancer treatment in vitro and in vivo.
Ceramic materials are also exploited for encapsulation and delivery of active molecules. Indeed,
these materials combine the therapeutic effect of the drug with the intrinsic biological activity
of the glass [158]. Ceramic materials such as silica, zinca and titania particles are commonly
used in the dermatological application since their cations exert antimicrobial activity, and their
morphology and surface properties may be tuned to enhance their bio-affinity [159–161]. Anirudhan
and Nair succeeded in the production of drug loaded mesoporous silica particles with a size range
of 200–300 nm [162]. The surface of these particles was grafted with oligomeric chains that acted as
thermally and ultrasound-activated gates for drug-controlled release. Biocompatibility was assessed by
keratinocytes cell culture assay while skin penetration was observed on excised rat skin. Xu et al. [163]
proposed a similar responsive system fully based on inorganic materials. The mesoporous silica
nanoparticles were loaded with insulin and capped with ZnO quantum dots. Enzymes were integrated
in the system in order to catalyze the conversion of glucose to gluconic acid above a certain sugar
concentration. The gluconic acid conversion led to local decrease of pH causing the degradation of
quantum dots and triggering the insulin release. The system was proved to be effective in modulating
the glucose level on rats.
Table 1 summarizes the described applications of nanocarriers in dermatological application. It is
observable how pharmaceutical nanocarriers have been employed for the release of both hydrophilic
and hydrophobic substances. The therapeutic target for which the systems were designed are various
and include both topical and transdermal formulations. Most of the reviewed work tested the produced
formulations onto porcine skin. Such choice can be interpreted considering the easiness in obtaining
pig skin and the proximity of the results obtained on this tissue with the human. In some cases,
the formulations were tested in vivo. The obtained results are promising in terms of advancement of
such technology toward the clinical trial experimentation stage.
Table 1. Characteristics and application of nanocarriers in dermatological therapies.
Drug Hydrophilicity Carrier TherapeuticIndication Experimentation Ref.
Vitamin D Hydrophobic Nanospheres Supplementadministration
Healthy and
damaged porcine
skin
[119]
Caffeine Hydrophilic Nanospheres Antioxidant andanti-cellulite Artificial Membrane [122]
Adapalene and
adapsone
Hydrophobic and
hydrophilic Nanocapsules Dermatitis treatment Porcine skin [123]
HNE inhibitor Hydrophobic Nanocapsules Psoriasis In vitro and in vivo(rats) [124]
Clobetasol
propionate Hydrophobic
Nanospheres and
nanocapsules Alopecia treatment
Ex vivo pig and
human skin [125]
Vancomycin Hydrophilic Nanobubbles Skin infection Porcine skin [128]
Rifampicin Hydrophobic Nanobubbles Acne treatment In vitro studies [127]
Imiquimod Hydrophobic Nanosponges Aberrant wounds Porcine skin [143]
Resveratrol Hydrophobic Nanosponges Antioxidant Porcine skin [144]
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Table 1. Cont.
Drug Hydrophilicity Carrier TherapeuticIndication Experimentation Ref.
Econazole
nitrate Hydrophobic Nanosponges Fungal infection In vitro studies [145]
Sodium
Fluorescein Hydrophilic Liposomes Model system Porcine skin [147]
Quercitin Slightly hydrophilic Liposomes Antioxidant Human excised skin [149]
Nobiletin Hydrophobic Hydrogel Acne treatment Porcine skin [156]
Heparin and
Paclitaxel
Hydrophilic and
hydrophobic Hydrogel
Transdermal cancer
therapy In vitro and in vivo [157]
5-fluroracil Hydrophilic Silica nanoparticles Cancer therapy Rat skin [162]
Insulin Hydrophobic
Silica nanoparticles
and ZnO quantum
dots
Transdermal diabetes
therapy In vivo in rats [163]
5. Bio-Functional Textiles
Pharmaceutical carriers are a promising strategy to provide skin delivery both at topical and
transdermal levels. Notwithstanding the efficacy of such carrier in penetrating the skin layers,
the application of the nanoformulations is not different from the classical ointments and creams.
These administration strategies still require multiple applications by the patient, and therefore do not
improve its compliance with the therapy. The strategy of immobilizing the nanocarriers onto textile
support was proposed in recent years to overcome this drawback. The obtained materials are defined
as bio-functional textiles and consist of a combination of pharmaceutical carriers with a conventional
textile material such as cotton, wool or man-made fibers. The great potential of bio-functional textiles
lies in the possibility of creating a wearable technology out of the pharmaceutical nanocarriers [47,164].
The application of pharmaceutical carriers to a textile generally occurs by mean of a finishing
treatment. This is in general the final unit operation of the textile manufacturing chain and aim to
impart desired properties to the fabrics both from the aesthetic and technical points of view. In the
design of bio-functional garments, the approach is to employ the well-known finishing techniques also
for pharmaceutical carriers loading. This approach at the laboratory scale aims to design more easily
scalable processes and ease technological transfer. These processes include padding, bath exhaustion,
spraying, and layer-by-layer deposition methods, which are sketched in Figure 3. In most cases, drying
and curing steps are performed in order to achieve a better fixation of the carriers onto the textile
surface [165–167]. According to the final applications, the process aims to control the final amount
of drugs loaded on the garments; moreover, the fixation treatment is designed in order to tune the
interaction strength between the fabric and the carriers. Such interactions play a primary role on the
carrier release and the fastness of the treatments [168,169]. The finishing step is realized by means of a
wet finishing process for carriers in liquid suspension forms [170]. Bath exhaustion is one of the oldest
finishing processes, and it consists of the immersion of the fabric in the finishing liquor. Temperature
and pH of the bath are adjusted in order to achieve the best thermodynamic affinity between the fibers
and the solution. This technology is batch type; it provides excellent uniformity of the treatment but
does also imply some waste of the finishing bath due to the high liquor ratio required [171,172].
Oppositely, padding is a continuous process that allows working with smaller liquor amounts.
In this technology, the fabric is quickly immersed in the finishing bath, then squeezed between two
rolls, which control the level of wet pick up by applying a given pressure. The padding bath generally
contains a binder to promote adhesion of the finishing agent. The padding process requires good affinity
with the textiles, and it may not be suitable for inert materials such as polyesters unless preliminary
surface activation is performed [173–175]. Spray techniques are also used for textile finishing; they can
be implemented in process line followed by fixation treatments. Recently, spray-based methodologies
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such as electrospraying have been proposed to produce the carriers, and therefore they might be a
novel approach for a single-step production and finishing process [176,177].
Layer-by-layer (LbL) deposition is a novel finishing technique that arose significant interest in
recent years. It consists of alternatively dipping the textile in oppositely charged electrolyte solutions,
allowing a precise number of monolayers to deposit on the fiber surface. This technique is widely
employed for thin film assembling and is available at pilot scale. All the described finishing techniques
can be applied for carrier application onto fabrics [178].
Figure 3. Finishing techniques for bio-functional textile production.
When a cross-linking agent is used, a curing step is usually performed to allow the formation of
chemical bonds between the fabric and the carriers, depending on the material end use and the desired
design [179]. Curing may require high temperature or UV radiation in order to effectively promote
chemical reactions, however, in the context of bio-functional textiles, particular care must be taken in
order to avoid drug degradation or carrier deterioration under the curing process conditions [172].
The produced bio-functional textiles are usually studied and tested at laboratory scale to assess
their performance. Characterization of the product aims at determining the effectiveness of the finishing
technique, which is commonly investigated by spectroscopy-based analysis such as attenuated total
reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and morphological observation by
scanning or transmission electron microscopy (SEM, TEM). Moreover, durability of the treatment is
usually tested in terms of washing fastness. This test is commonly conducted by washing the textile
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material several times, according to textile norms and standards, and repeating the ATR-FTIR and SEM
analysis to qualify and quantify the residual drug on the fabric [41,180,181]. Pharmaceutical analyses
are instead aimed to evaluate the potential effect of the product on the living body. They usually are
designed according to the therapeutic target of the bio-functional textile. The transdermal release
is usually evaluated by the Franz diffusion cell method, which is the test recommended by the
pharmacopeia for dermal and transdermal formulations. The Franz cell consists of a vessel divided
into a donor and acceptor compartments; the acceptor one is filled with a blood mimicking solution,
while the formulation is placed in the donor one. The two compartments are separated by a membrane,
which mimics the skin; it can be constituted by artificial or real skin obtained from rat, pigs, or human
donors [182,183]. The kind of membrane used in the test is the main variable in determining the overall
results, and recently many attentions have been paid on it. The group of Martì recently proposed the use
of novel artificial membranes enriched with SC mimicking lanolin which could combine the desirable
low variability of artificial membranes while maintaining the diversified layer composition typical of
real skin [184]. A complete review of the physical and chemical properties of excised skin was done by
Todo, who also analyzed the possible effect on a transdermal penetration test [185]. Cell cultures are
also a widely used tool to assess bio-functional textile in in-vitro performance. They are commonly used
to either test the product compatibility with healthy skin cells or to evaluate the capability of the textile
to protect the person from harmful microorganisms. In the first case, the cell culture is made of skin
keratinocytes or corneocytes, cell viability may be measured by methylthiazolyldiphenyl-tetrazolium
bromide (MTT) or Lactate dehydrogenase (LDH) assays [186,187]. In the second case, the microbial
growth inhibition is conducted on model bacteria, such as the gram-positive Staphilococcus Aureus
or the gram-negative Escherichia Coli, or fungi such as Candida Albicans. The antimicrobial tests are
realized according to several standard protocols, and many authors repeated them after washing the
textile in order to assess the antimicrobial finishing fastness [172,186,188]. Lastly, non-invasive in-vivo
methodologies consist in applying the textile on the skin of human volunteers in the form of a patch
test and subsequently obtain data on the skin condition by different methods such as tape striping or
transepidermal water loss measurement (TEWL) [189].
Our research group proposed the finishing of cotton fabrics with polycaprolactone (PCL)
nanospheres. The particles were produced by Flash nanoprecipitation method exploiting the confined
impinging jet reactor. Several drugs were loaded in the particles and thereafter applied to cotton
by simple imbibition in order to enhance the detachment of the nanospheres from the textile [190].
The garments were tested according to the effect of the loaded substances. In the case of menthol-loaded
textiles, aimed to provide topical refreshment feeling to the wearer, they were applied on a set of
volunteers in a double blind protocol, the subjects were interviewed and skin parameter measured,
proving that the functionalized cotton can provide refreshment without causing skin irritation [189].
The study conducted on melatonin-loaded fabrics was aimed at promoting drug crossing through
the skin membrane and reaching the systemic circulation. Therefore, the functionalized fabric was
mounted on a Franz cell, and this study proved an effective release of the drug through the skin
mimicking membrane [164].
Micro- and nanocapsules are among the most employed carriers employed in textile finishing
for a wide range of applications [107,191]. In the context of bio-functional garments, various kinds
of core substances and shell materials can be combined in the capsule formation in order to impart
health beneficial properties. In the work of Yang et al. [192], a spray drying method was employed to
incorporate vanillin in a chitosan shell, the capsules were grafted on cotton fabrics by a bath exhaustion
protocol in which citric acid was added to promote crosslinking. The obtained textile exhibited
high washing fastness due to the chemical bonds between chitosan shell and the cellulose fabric.
Ghayempour et al. [193] have recently incorporated the hydrophilic chamomile extracts via a double
emulsion method, the obtained capsules where mixed with an acrylic resin and applied to cotton fabric,
the resin was crosslinked by UV curing. Such an approach led to slow release and high washing fastness
due to presence of the capsules and the resins hindering the extract diffusion. Furtherly, the hindered
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diffusion did not compromise the antimicrobial activity of the extracts retained throughout several
washing procedures. According to Martì et al. [168], the application of the capsules by resin finishing
may cause considerable alteration on the transdermal release kinetics. The transdermal release occurs
by diffusion phenomena, the driving forces depending on the concentration gradient, which is affected
by the amount of drug contained in the fabric. For this reason, this study focuses on evaluating the
effective drug loading of the fabric upon treatment with microcapsules and liposomes. The application
was performed by padding process onto cotton, polyamide (PA), polyacrylic (PAC) and polyester (PES).
The substance was extracted both by soxhlet extraction and ultrasound bath and quantified by UV-vis
spectroscopy and HPLC. The work proved that in the carrier loading onto different fabrics the great
role is played by surface interactions and chemical affinities between the carrier shell and the fiber [168].
The same research group intensely studied the transdermal release from fabrics functionalized with
liposomes. Firstly, they investigated the release of caffeine from liposomes attached onto cotton
surface by comparing the results of Franz Cell experiments performed with synthetic membrane and
porcine skin [194]. In the following test, the bio-functional textiles were also functionalized with
liposomes produced with internal wool lipids in place of phosphatidylcholine. For these material tests,
a non-invasive in vivo test methodology was also introduced [195].
Cyclodextrins (CDs)-based finishes have been widely exploited in recent years. Martel’s group
proposed a methodology that allows the chemical modification of cyclodextrins to impart positive
and negative surface charges [196]. After cationization or anionization, the CDs were loaded with
4-tert-butylbenzoic acid (TBBA) and deposited on a polyester substrate by LbL deposition. The polyester
substrate was preliminarily activated by plasma treatment, and after deposition, the material underwent
thermal curing in order to promote the formation of chemical bonds between the oppositely charged
cyclodextrins layers. A controlled release profile was assessed by a flow through cell apparatus and
cell culture proved both the non-cytotoxicity and the antimicrobial activity [188]. Mihailiasa et al. [197]
synthesized cyclodextrin nanosponges by chemical crosslinking. The crosslinking was proven to be
useful to improve drug loading. Moreover, the loaded nanosponges were applied on cotton fabrics
by bath exhaustion process and the treatment exhibited fastness for two washing cycles. The release
test on Franz cell showed zero-order release kinetics. Maestà Bezerra et al. [198] produced similar
crosslinked cyclodextrin systems which were employed for the incorporation of citronella oil. The CDs
were applied on wool fabrics by padding method, the overall system presented an anomalous release
kinetics according to the Korsmeyer and Peppas’s model.
Textile finishing with inorganic particles was proposed by Hassabo et al. [199], who incorporated
various topical medicaments such as diclofenac and linoleic acid into silica nanoparticles. The particles
were synthetized with the Staber method using TEOS as precursor and applied to cotton by a
spray-based methodology. The release test proved the release of the active substance in dermal pH
condition and the antimicrobial activity against several species. A combination of organic and inorganic
particles was proposed by Perelshtein et al. [200], which employed sonodynamic deposition method.
This approach allowed the direct assembly of the particles onto the cotton surface eliminating, therefore,
the need for a finishing treatment. The combination of zinc oxide (ZnO) and chitosan significantly
improved the antimicrobial activity compared to the single agents and the use of ZnO particles also
imparted UV protection properties to the garment. The use of hydrogels in the context of bio-functional
textile preparation was proven to be an effective strategy to provide drug administration and moisture
management simultaneously [155]. The work of Hui et al. [186,187] exploited an emulsion cross
link process to produce chitosan hydrogels loaded with Chinese herbal medicines. The obtained
carriers were applied to cotton fabrics by exploiting the pad-dry-cure method with a chemical binder.
The MTT and LDH tests confirmed the non-cytotoxicity of the material while the release test displayed a
sustained drug administration for an entire week. The system was considered suitable for treatments of
atopic dermatitis and other topical applications due to micrometric size of the carriers, which prevented
transdermal permeation.
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Petrusic et al. [201] proposed micro-hydrogel for the design of stimuli response drug releasing
textiles. The hydrogel was constituted of a thermo-responsive polymer (Poly(N-isopropylacrylamide)),
which undergoes significant swelling in the range of skin temperatures. Hydrogels were prepared
from an inverse suspension polymerization method. The Franz cell experiments were conducted
at different temperatures and shown that the thermosensitive hydrogels are an effective strategy
to control the amount of procaine released [201,202]. Table 2 reports the described characteristics
and application of bio-functional textiles. It can be observed that cotton fabrics are among the most
exploited textile material for this specific application. Such observation can be easily explained by
considering comfort and biocompatibility of cellulosic material such as cotton. Furtherly, cotton is
extremely wettable and therefore surface functionalization can be easily performed by wet finishing
treatments. The applications of bio-functionalized textile materials are of different kinds: in all the
cases, however, an active substance with specific therapeutic or cosmetic properties is released from
the textile system. The finishing treatments that have been employed for bio-functionalization are
diverse; the choice of each author made on the basis the final application. The objective is selecting the
functionalization process that will promote the right interaction among the carriers and the fibers in
order to achieve the desired properties in terms of fastness and controlled release. The opportunity of
adapting the textile finishing processes to different pharmaceutical carriers is promising in terms of
process scalability.
Table 2. Characteristics and application of bio-functional textiles.
Carrier Active Substance Textile Carrier FinishingTechnique Application Reference
Poly-ε-caprolactone
(PCL) nanospheres Melatonin Cotton PCL nanospheres Imbibition
Transdermal
delivery [164]
PCL nanospheres Menthol Cotton PCL nanospheres Imbibition Thermalregulation [189,190]
PCL nanospheres Caffeine Cotton/Micromodal PCL nanospheres Imbibition
Antioxidant
activity [121,122]
Chitosan
microcapsules Vanillin Cotton
Chitosan
microcapsules
Bath Exhaustion/
Crosslinking
Antibacterial and
aroma release [192]
Chitosan
microcapsules
Chamomile
extracts Cotton
Chitosan
microcapsules
Resin
finishing/UV
curing
Topical
antibacterial [193]
Liposomes and
microcapsules Sunscreen
Cotton, PA, PAC,
PES.
Liposomes and
microcapsules Foulard UV protection [168]
Liposomes Sunscreen Cotton Liposomes Bath Exhaustion UV Protection [195]
Liposomes Caffeine Cotton Liposomes Imbibition Transdermaladministration [194]
Cyclodextrins 4-tert-butylbenzoicacid (TBBA) polyester (PES) Cyclodextrins
Layer by layer
deposition
Topical infections
treatment [188,196]
Cyclodextrin
nanosponges Melatonin Cotton
Cyclodextrin
nanosponges Bath Exhaustion
Transdermal
release [197]
Cyclodextrin Citronella oil Wool Cyclodextrin Padding Insect repellency [198]
Silica nanoparticles Diclofenac Cotton Silicananoparticles Spray Topical treatment [199]
Chitosan hydrogel Chinese Herbalextract Cotton Chitosan hydrogel Pad-dry curing Topical treatment [186,187]
6. Bio-Functional Textiles and Other Dermatological Delivery Technologies
To better understand the significance and the potential of the bio-functional textile approach,
other technologies aimed to deliver drugs to and across the skin are analyzed and discussed.
Conceptually similar to bio-functional fabrics, electrospun nanofibers have gained significant
interest in the context of biomedical research over the last years [203,204]. Such materials consist of fiber
mats with a diameter below the micrometer. These nanofibers are obtained through the electrospinning
process, consisting of spinning a viscous polymer solution in a high voltage electrical field. The fibers are
collected on a metal plate and during the way from the tip to the collector, the solvent evaporates allowing
a dry fiber mat to be collected [205,206]. The process is very versatile and allows spinning of different
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polymers. Therefore, in the context of biomedical applications, several bio compatible polymers,
such as PCL, chitosan, silk fibroin, keratin, alginate, etc. have been electrospun. Moreover, drugs or
drug loaded nanocarriers can be introduced in the viscous solution, therefore spinning drug eluting
nanofibers [207,208]. In the frame of dermal therapy, this approach is very promising for wound
recovery application. Indeed, wound therapy requires both the promotion of the cellular regrowth and
the administration of drugs to fight bacterial infections. Drug-loaded nanofibers can elute drugs on the
damaged tissue to prevent bacterial growth. Moreover, their structure was found to be very similar to
the extracellular matrix from the morphological point of view; therefore, this material can promote
healthy cells regrowth [208,209].
Microneedles (MN) technology consists of the production of patches equipped with several arrays
of needle of small size. The aim of MNs is to inject the drug inside the deeper vascularized skin
layers by creating micron sized holes in the epidermis. Thus, such technology overcomes the issues of
permeation trough the epidermal layer. MN can load drug in the patch, in the tip of needle or just on
its surface [102,210]. The material used to fabricate the needle can be a metallic, ceramic or polymeric
compound [211]. In the recent years the polymeric MNs have aroused the greatest interest.
Indeed, they have been proven to be cost effective due to the lower cost of polymeric material
and for the simplicity of the production process. Furthermore, in some cases the polymer itself
is bioabsorbable and degrades inside the dermis. To achieve these effects, the polymer must be
biodegraded in dermal physiological conditions, for this reason polymer like Polylactic acid (PLA),
Polyvinylpyrrolidone (PVP) and chitosan are usually preferred [212]. The possibility of delivering
the drug in vascularized dermis avoiding a fraction of the drug to be blocked in SC made MNs
among the most effective transdermal technology. On the other hand, some concerns are usually
raised by the high invasiveness of such a technique which indeed pierces and holes the skin and
may cause irritation. For these reasons, MNs may be considered an effective approach to administer
drugs such as insulin and chemotherapeutics. These drugs are generally quite expensive, so their
administration must be maximized. Moreover, their common administration route is the parenteral one
and therefore MN is a novel and less invasive administration route [213,214]. Other skin penetration
technologies imply the use of external stimuli in order to promote the permeation of the therapeutic
agent in the epidermis [215]. Sonophoresis exploits ultrasounds to enhance the permeation by
disrupting the Stratum Corneum [216]. Sonophoresis can be operated either at therapeutic frequencies
(1–3 MHz) or at low frequencies (20–100 kHz). The mechanism of penetration enhancement by
sonophoresis is still to be fully understood. The main proposed effects are the acoustic cavitation of
gas microbubbles that causes the disruption of the extracellular lipids in the SC. Moreover, permeation
is enhanced by a local gradient of temperature generated by the ultrasound energy, which plays a
role in promoting diffusion [216,217]. The employment of low frequency sonophoresis was proved to
be efficient in promoting the permeation of high MW molecules or small hydrophilic ones [101,218].
However, the effects of penetration enhancement and the pharmacokinetics upon the ultrasound
treatment significantly vary on the kind of drug under investigation [219]. The enhancement of skin
penetration obtained by applying an electrical stimulus is defined as iontophoresis. This technique
employs low electrical currents (below 0.5 mA/cm2) to promote the active molecules permeation
through the epidermis. Concerning the electrically promoted transdermal transport mechanism,
two main phenomena have been identified. The electrophoretic mechanism is mainly based on the
repulsion of the drug from the electrode induced by the applied current, the drug is in this way pushed
to cross the skin barrier [17]. The electroosmotic mechanism works in parallel with the electrophoretic
one and can either promote or hinder drug permeation. In fact, considering the epidermis as a
porous membrane in which the charges are balanced, the application of an electrical current would
cause an ion flux across the membrane. Therefore, the drug transport based on iontophoresis will
be strongly influenced by the polarity and surface charge of the species to be delivered and on the
pH of the skin [220]. The penetration route enhanced by iontophoresis is mostly the annexial one.
Indeed, iontophoresis has been widely studied to promote penetration of different kind of drugs or
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the transport of surface charged polymeric nanocarriers [221]. In order to apply the iontophoresis
technique, the drug must be charged and satisfy certain polarity requirements [100]. To critically
compare the mentioned technologies, several prospective should be considered. In Table 3 the main
aspect related to transdermal technologies are compared.
Table 3. Comparison among different transdermal technologies.
Bio-Functional Textiles Microneedles Sonophoresis Iontophoresis
Drug applicability Drugs deliverable bynanocarrier system Most of the drugs Small substances
Charged and
polar drugs
Penetration
mechanism
Complex: release from
textile + transdermal
penetration
Simple: direct release
in the epidermis
Transdermal
penetration +
cavitation
Electro osmosis and
electrophoresis
Control of dosage Lower due tocomplex release Very Good Fair Fair
Patient usability Simple to wear Simple patchapplication
Ultrasound device
needed
Electrical current to be
applied
Administration
required Few Few Several Several
Possible side effect None reported Skin piercing andirritation
Stratum Corneum (SC)
disrupted Surface damages
Concerning the kind of drugs that can be delivered by each system ionto- and sonophoresis present
strict limitations compared to MN and bio-functional textiles. In fact, once the active substance is
incorporated in the carriers and in the MN the release kinetics is less affected by the chemical structure
of the therapeutic molecule. The release phenomena occurring are also of different nature. In MNs
the permeation of the epidermis is bypassed, making the release from this technology more effective,
while in bio-functional textiles, the permeation mechanism is mostly dominated by passive diffusion.
A textile-based delivery system could potentially be applied to all the drugs that are deliverable by
a nanocarrier system. Therefore, it can be stated that bio-functional textiles own the potential of
administering numerous kinds of drugs. Concerning the control of delivered dosage, it can be stated
that its accuracy is strictly related to the complexity of the release mechanism. MNs indeed offer the
best dosage control since the needle system penetrates the epidermis and dissolves in the vascularized
dermis releasing the total amount of drug loaded in the needle. Ionto- and sonophoresis require,
instead, the drug to permeate all the layers of the skin undergoing the already discussed slowing-down
or accumulation phenomena which makes the control of the dosage less accurate compared to MNs.
A further level of complexity is found in the textile systems. Here the drug is generally encapsulated
and therefore the permeation phenomenon is a combination of the carrier penetration together with
the release of the drug from the carrier, two mechanisms that have different characteristics times and
potentially overlap. Moreover, the kinetics of release of the carriers from the textiles plays a critical
role in the overall drug administration process. For this reason, the overall release of drugs from
a bio-functional textile is more complicated with respect to the other systems and is yet to be fully
understood in order to achieve an effective control of the dosage. Concerning the invasiveness of
the systems, MNs require the outer layers of the skin to be perforated. Furthermore, if the polymer
swells inside the epidermis, the needles enlarge, causing the micropuncture to increase in size. Ionto-
and sonophoresis require external stimuli that may perhaps damage skin integrity. Moreover, proper
devices should be used to apply electricity and ultrasounds. Therefore, ionto- and sonophoresis are
more difficult to be operated by the patient without medical supervision. Bio-functional textiles are
instead quite simple to be applied since they can be worn as conventional garments or bandages.
Moreover, their application has never been reported to cause side effects on the patient’s skin. It can be
observed that bio-functional textiles are a promising technology under many points of view. Their main
current weakness is the scarce control over the amount and kinetics of drug release related to high
complexity of phenomena occurring. However, such limitations may be overcome in the coming years
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upon the conduction of proper research and studies. Indeed, the research efforts necessary to optimize
these systems may be worthwhile, providing their great advantages in terms of biocompatibility,
easiness and versatility.
7. Regulatory Status
Given the great potential and interest in the development of bio-functional textiles, an overview
of the regulatory status of such devices is provided in order to better understand the challenges and
opportunities of such materials in reaching the market. The application of nanomaterials in wound care
and medical textiles is rapidly increasing. Considering the current regulatory status, the classification
of a textile product should consider several aspects. A textile containing active molecules loaded in
nanocarriers can be considered either a medical device, a cosmetic or a medicinal product, according to
the type of encapsulated molecule and the permeation profile. Moreover, it is worth underlining
that a drug incorporated in a medical device must have only an ancillary function, otherwise the
product must follow the regulation of medicinal products [222]. In addition, the current European
regulatory framework supervising the presence of nanomaterials in healthcare products is complicated,
because it is not well-defined and not yet harmonized. Nevertheless, Regulatory Agencies required
manufacturers to perform accurate studies for assessing the quality, safety, and efficacy profile of a
nanotechnology-based product [223]. In July 2007, the Nanotechnology Task Force of FDA prepared a
report presenting an assessment of scientific and regulatory considerations relating to the safety and
effectiveness of FDA-regulated products containing nanomaterials. Moreover, the FDA has issued
several additional guidance documents to industry in order to provide recommendations for evaluating
the application of nanotechnology in FDA-regulated products [224–226]. The safety of a product
containing nanomaterials is a key factor to be assessed. A risk management strategy is required in order
to market nanoparticle-loaded medical devices. In January 2015, the European Scientific Committee on
Emerging and Newly Identified Health Risks (SCENIHR) adopted an Opinion on the “Guidance on
the determination of potential health effects of nanomaterials used in medical devices”. This Guidance
provides information about the safety evaluation of nanomaterials, i.e., the determination of hazards
associated with the use of nanomaterials and risk assessment for the use of nanomaterials in medical
devices [227]. The ISO guideline (EN ISO 10993) concerning the biological evaluation of medical
devices reports the basis for the biological safety tests for textiles. This indicates which risk analyses
and test (i.e., cytotoxicity, tissue compatibility, sensitization and irritation potential evaluation) need to
be carried out [228]. In addition, there is a stricter classification for devices containing nanomaterials,
considering the potential internal exposure to nanoparticles caused by the application of such a
product. As far as the FDA is concerned, existing regulations have been adapted for medical devices
with nanoparticulate components. A medical device containing nanomaterials should undergo
premarket testing and approval under the Premarket Approval Application (PMA), if the inclusion of
nanomaterials requires original clinical study data to ensure the safety of the nanoproduct. Indeed,
this approval process requires clinical trials and/or other evidence to demonstrate the safety and
effectiveness of the device [229,230]. Conversely, the application of nanomaterials in cosmetics is
well-defined and regulated. Regulation (CE) No 1223/2009 introduced specific requirements for
marketing cosmetic products containing nanomaterials. Responsible persons (i.e., manufacturers,
importers or third persons appointed by them) are required to register cosmetic products on the
cosmetic products notification portal (CPNP), specifying the presence of nanomaterials in the product,
together with their identification and the foreseeable exposure conditions. Moreover, if the European
Commission has concerns regarding the safety of a nanomaterial, it may request the scientific committee
on consumer safety (SCCS) to perform a risk assessment [231]. FDA provides guidelines to industry
on the safety assessment of nanomaterials in cosmetic products. The guidance documents help to
identify the potential safety issues of nanomaterials in cosmetic products and develop a framework for
evaluating them. In particular, the safety of a cosmetic product containing nanomaterials should be
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evaluated by analyzing the physicochemical properties and the relevant toxicological endpoints of
each ingredient in relation to the expected exposure [232].
8. Conclusions
The present review covered the research conducted in the recent year on the application of
textiles materials as transdermal delivery devices. The structure of the skin was deeply described
from the chemical biological point of view. This allowed us to have a clearer understanding of such a
complex organ both as a therapeutic target or as a barrier to be crossed to deliver the drug systemically.
The possible interactions of drug with skin were discussed with a focus on the different pathways of
transdermal administration. It clearly emerged that transdermal penetration is influenced by several
complex phenomena that are hindering its wider application. The application of pharmaceutical
nanocarriers was therefore analyzed as a novel strategy to overcome the skin barrier. Indeed, it was
discussed how many encapsulation technologies have nowadays proved their efficacy in enhancing
skin penetration. Moreover, such technology showed to be quite versatile and able to deliver different
kinds of active substances for various applications. Bio-functional textiles were therefore presented
as a combination of these carriers with textile fabrics. The different methods to apply the carriers on
the fabrics were discussed. It was shown that common textile finishing apparatus are suitable for the
carrier application. The literature review of the novel bio-functional textiles showed the possibility
of developing garments with beneficial properties to human health. The bio-functional textiles
technology was critically compared with other transdermal penetration approaches. It was clearly
evidenced that its versatility and compatibility make bio-functional textile technology significantly
advantageous. The regulatory analysis evidenced how the commercialization of a bio-functional
textile may depend on the product characteristics in terms of incorporated substance and employed
nanocarrier. The literature review here conducted provided a broad view on a topic that matches
pharmaceutical and healthcare industry with the textiles one. It can be concluded that the emerging
technology of bio-functional textiles is a link between these two sectors since it matches the most
advanced pharmaceutical technologies with the smart textiles technologies.
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